#USA #Aignostics #AI App #Atlas HE-TME #Berlin, New York

Aignostics Launches Atlas HE-TME

Berlin and New York, October 15, 2025 – Following successful early access pilots with leading biopharmaceutical partners, Aignostics today announced the general availability of Atlas HE-TME, an innovative application designed to analyze tumor microenvironments (TME) from routine hematoxylin and eosin (HE) stained slides. This groundbreaking technology addresses a significant barrier in cancer research, extracting detailed information without the need for specialized staining or multiplexing.

Atlas HE-TME facilitates a comprehensive analysis of entire slide images in just hours, enabling researchers to quickly characterize immune cell populations, spatial relationships, and tissue architecture across a variety of cancer types. This application has been meticulously developed using Atlas, a leading foundational model co-developed by Aignostics, Mayo Clinic, and Charité Berlin. The app provides precise quality control readings, covering seven tissue types, nine cellular classes, and over 5,000 quantitative metrics per image.

Aignostics' application is available as a self-service tool, with future integrations expected with major image management systems. It has undergone extensive validation across primary and metastatic sites from multiple laboratories and scanners to ensure its applicability in real-world conditions. Validated performance metrics can be provided to new partners upon request.

Dr. Frederick Klauschen, co-founder of Aignostics and Director of the Institute of Pathology at Ludwig Maximilians University Munich, praised the app, stating, "This is the first time I see a model demonstrating consistently high accuracy across multiple cancer indications with exceptional robustness." He emphasized that understanding the TME is crucial for developing effective cancer therapies, pointing out that traditional methods are often costly, time-consuming, and limited in scalability.

Viktor Matyas, co-founder and CEO of Aignostics, added that Atlas HE-TME transforms existing paradigms in cancer research. “Our pilot projects with the biopharmaceutical industry confirmed that we can deliver high-quality results with unmatched accuracy, speed, and scale, empowering researchers to maximize the utility of every HE image.”

The application supports various research use cases, from swiftly identifying and characterizing tumors with immune infiltration to integrating HE data with spatial transcriptomics for refined cellular niche analyses. Initially available for partners researching breast, bladder, colorectal, liver, and lung cancers, access will gradually expand to academic institutions and cover additional cancer types and analyses in the coming months. Interested organizations can visit Aignostics' website for more information on obtaining a free trial.

About Aignostics

Founded in 2020 as a spin-off from Charité Berlin, Aignostics is an artificial intelligence company dedicated to transforming complex pathological data into actionable insights for precision medicine. The company leverages exclusive access to multimodal clinical data, industry-leading AI technologies, and a rigorous scientific approach. Aignostics develops premiere products and services supporting the entire drug development process, from discovery and translational research to clinical trials and complementary diagnostics. With the launch of Atlas HE-TME, Aignostics is poised to redefine tumor microenvironment profiling, providing researchers with unprecedented accuracy and scalability. The company is backed by prominent investors and employs over 120 professionals, operating in Berlin and New York.

For more information, visit www.aignostics.com and follow us on LinkedIn at Aignostics LinkedIn.